Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hydrogen Peroxide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Radiotherapy + radiation sensitizer | EXPERIMENTAL | Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer |
| Radiotherapy alone | NO_INTERVENTION | Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone. |
| Name | Type | Description |
|---|---|---|
| Hydrogen Peroxide | DRUG | Hydrogen Peroxide |
Inclusion Criteria: * Age over 18 years * Primary locally advanced breast cancer, or locally recurrent breast cancer with/without metastases * Radical/high dose palliative radiotherapy required for lifetime control of local morbidities * Patient physically and mentally fit for radical/high dose pal...
Top 20 of 92 competitors
Hydrogen Peroxide is being studied as an intra-tumoural radiation sensitizer in patients with locally advanced or recurrent breast cancer. It is administered directly into the tumour to enhance the effects of radiation therapy. The drug is currently in Phase 1 clinical development for this oncology indication.
Hydrogen Peroxide does not target a specific molecular target. Instead, it acts as a radiation sensitizer when injected intra-tumourally. Its mechanism involves increasing the oxygen concentration in the tumour microenvironment, which can enhance the effectiveness of radiation therapy in treating breast cancer.
Hydrogen Peroxide is being developed by United Therapeutics Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research to evaluate the drug's safety and efficacy as a radiation sensitizer for breast cancer treatment.
Hydrogen Peroxide is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to assess its toxicity and tumour response when used as an intra-tumoural radiation sensitizer in breast cancer patients.
Hydrogen Peroxide has one completed Phase 1 clinical trial registered under NCT02757651. The trial, titled 'KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,' enrolled 12 participants in the United Kingdom.
Hydrogen Peroxide is the active drug being studied in the KORTUC clinical trial. KORTUC is the trial acronym, not an alternative name for the drug itself. The trial evaluates intra-tumoural hydrogen peroxide as a radiation sensitizer for locally advanced or recurrent breast cancer.